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X-linked infantile spinal muscular atrophy (XL-SMA) is an X-linked disorder presenting with the clinical features hypotonia, areﬂexia,
and multiple congenital contractures (arthrogryposis) associated with loss of anterior horn cells and infantile death. To identify the
XL-SMA disease gene, we performed large-scale mutation analysis in genes located between markers DXS8080 and DXS7132
(Xp11.3–Xq11.1). This resulted in detection of three rare novel variants in exon 15 of UBE1 that segregate with disease: two missense
mutations (c.1617 G/T, p.Met539Ile; c.1639 A/G, p.Ser547Gly) present each in one XL-SMA family, and one synonymous C/T
substitution (c.1731 C/T, p.Asn577Asn) identiﬁed in another three unrelated families. Absence of the missense mutations was dem-
onstrated for 3550 and absence of the synonymous mutation was shown in 7914 control X chromosomes; therefore, these results
yielded statistical signiﬁcant evidence for the association of the synonymous substitution and the twomissensemutations with XL-SMA
(p¼ 2.4163 1010, p¼ 0.001815).We also demonstrated that the synonymous C/T substitution leads to signiﬁcant reduction of UBE1
expression and alters the methylation pattern of exon 15, implying a plausible role of this DNA element in developmental UBE1 expres-
sion in humans. Our observations indicate ﬁrst that XL-SMA is part of a growing list of neurodegenerative disorders associated with
defects in the ubiquitin-proteasome pathway and second that synonymous C/T transitions might have the potential to affect gene
expression.Motor neuron diseases (MND) represent a heterogeneous
group of disorders with respect to clinical presentation, dis-
ease course, genetic identity, underlying mutations, and
etiologies. They are generally characterized by weakness
due to muscle atrophy and/or spastic paralysis reﬂecting
the selective involvement of lower and/or upper motor
neurons. The most common childhood motor neuron dis-
eases are the autosomal-recessive (AR)-proximal spinalmus-
cular atrophies (AR-SMA) associated with deterioration
and destruction of anterior horn cells1 (MIM #253300,
MIM #253550, MIM #253400). These disorders, which are
caused by mutations in the SMN1 gene (MIM *600354,
GenBank accession number NM_000344), are often fatal,
leading to progressive symmetrical limb and trunk paraly-
sis and severe muscle atrophy. Considerable clinical het-
erogeneity has been reported.2,3 It has long been suggested
that a distinct X-linked SMA syndrome exists, similar to
Type I SMA (MIM #253300), but associated with congeni-
tal contractures (and fractures). This syndrome may be
related to arthrogryposis (ARGY), a complex clinical phe-
notype involving multiple congenital contractures and
limited movement of multiple body areas, more often dis-
tal than proximal.4 Over the last decade, we have come
to appreciate a previously unrecognized form of SMA
(X-linked infantile spinal muscular atrophy [XL-SMA] [MIM
%301830]), which indeed presents with the clinical char-188 The American Journal of Human Genetics 82, 188–193, Januaryacteristics of hypotonia, areﬂexia, and multiple congenital
contractures (arthrogryposis) associated with loss of ante-
rior horn cells and death in infancy.5 Based on our cumu-
lative experience, we have constructed a list of the deﬁning
features and laboratory ﬁndings associated with XL-SMA.
These can be described as follows: congenital hypotonia;
arthrogryposis 5 bone fractures; dysmorphic features, in-
cluding myopathic facies and digital contractures; death
of at least one affected within 1 year of birth, due to respi-
ratory distress; family history of miscarriages/spontaneous
abortions; genital abnormality (undescended testes); mus-
cle biopsy conﬁrmation of neurogenic atrophy; electro-
myogram (EMG) indicative of denervation; and autopsy
showing anterior horn cell loss. In 1995, we deﬁned a peri-
centromeric candidate interval for XL-SMA in Xp11.3–
Xq11.2 with positive LOD scores between markers MAOB
and DXS991.6 Through further analysis of additional
XL-SMA families via numerous microsatellite and SNP
markers, we recently conﬁrmed and slightly narrowed
this linkage interval to an approximately 20.4 Mb region
between markers DXS8080 and DXS7132 in Xp11.3–
Xq11.1.5 To identify the underlying disease gene, we now
established a gene catalog in the reﬁned interval and per-
formed mutation screening in 123 genes by applying a
direct sequencing approach. This approach was carried
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Table 1. Detected Mutations in Six Screened XL-SMA Families
XL-SMA Families Origin Detected Mutation
Mutation-Negative
X Chromosomes
Family #2 N. American/white c.1731 C/T p.Asn577Asn 7914
Family #4 N. American/white c.1731 C/T p.Asn577Asn 7914
Family #5 N. American/white c.1617 G/T p.Met539Ile 3550
Family #7 N. American/white c.1639 A/G p.Ser547Gly 3550
Family #9 Mexican No mutation -
Family #15 Thai c.1731 C/T p.Asn577Asn 7914
A total of 3550 control X chromosomes were screened for the three mutations by DHPLC or a direct sequencing approach. Out of these, 3300 X chromosomes
were derived from 1650 white females and 250 X chromosomes from healthy white males. DHPLC analysis (WAVE, Transgenomics) was performed under the
following conditions: gradient of B buffer, 58%–68%; running temperature, 62C; forward primer, TAA GTG AGC TTT GTT CCC C; reverse primer, CAG ATG CCT
GGC CTC TTT C. Another 4364 X chromosomes were screened for the synonymous C/T substitution by MALDI-TOF mass spectrometer analysis. Out of these,
4350 X chromosomes were derived from 2175 white females and 14 X chromosomes from healthy white males. MALDI-TOF analysis (Sequenom MassArray
system) was performed by the homogeneous mass extension (hME) process for producing primer extension products.21 Assays were designed with the
SpectroDesigner software. Primer sequences are available upon request.intronic sequences and on cDNA. DNA and RNA were
extracted from blood samples, ﬁbroblast cell lines, and im-
mortalized lymphoblastoid cell lines. The screening was
performed in a total of six XL-SMA families. All human
subject activities occurred in compliance with an active
human subject protocol, which has institutional approval.
Patient’s identiﬁcation and recruitment are described in
detail by Dressman et al. (2007).5 In brief, all families
were ascertained based on affectedmales showing diagnos-
tic features described above. Patients meeting study criteria
were recruited and consent was obtained by standard pro-
cedures. These screening efforts resulted not only in the
detection of a number of known polymorphisms in several
genes (data not shown), but importantly in the detection of
two novel missense mutations (c.1617 G/T, p.Met539Ile;
c.1639 A/G, p.Ser547Gly) in two families (families #5 and
#7) and a novel synonymous C/T substitution (c.1731
C/T, p.Asn577Asn) in the index patients of another three
families (families #2, #4, #15). All aberrations are located in
exon 15 of the UBE1 gene (MIM *314370; GenBank acces-
sion numbers NM_003334 and NM_153280) (Table 1, Fig-
ures 1 and 2). Sequences of used primer pairs for UBE1
screening are available on request. Interestingly, the gene
is located within a 2.4 Mb interval described as a potential
hotspot for neurogenetic disorders.7 UBE1 codes for theThe Aubiquitin-activating enzyme E1 that catalyzes in the ubiq-
uitin-proteasome system (UPS), the ﬁrst step in ubiquitin
conjugation to mark cellular proteins for degradation.8,9
The UPS, as a ubiquitin-dependent proteolysis system, is a
fundamental cellular mechanism for regulating protein
activity.10 The three mutations segregate with disease in
the families (Figure 1) and were shown by DHPLC analysis
(WAVE, Transgenomics) or direct sequencing approaches
to be absent in 3550 control X chromosomes (Table 1).
Additionally, 4364 control X chromosomes were nega-
tively screened for the synonymous C/T substitution
by MALDI-TOF mass spectrometer analysis (Sequenom
MassArray system), and therefore a total of 7914 X chro-
mosomes were shown to be negative for this alteration
(Table 1). Strictly anonymized DNA of unrelated control
individuals was provided by the German Breast Cancer
Consortium and the UM/MHRI Cardiovascular Genetics
Laboratory in Miami.
With two-sided Fisher’s exact tests as implemented in R
software (release 2.4.1), these numbers yielded statistical
signiﬁcant evidence for an association of the synonymous
substitution and the twomissensemutations with XL-SMA
(synonymous mutation: p ¼ 2.416 3 1010, OR ¼ inﬁnite,
95% conﬁdence interval 693.15 to inﬁnite; missensemuta-
tions: p ¼ 0.001815; OR ¼ inﬁnite, 95 conﬁdence intervalFigure 1. Pedigree of XL-SMA Family #2
As described by Kobayashi et al.6 Affected
males are indicated by black boxes, obli-
gate carriers with a dotted circle. The index
patient is marked with an arrow. The
synonymous C/T substitution (c.1731
C/T, p.Asn577Asn) was shown by direct
sequencing approaches to segregate with
disease in the family.merican Journal of Human Genetics 82, 188–193, January 2008 189
14.10 to inﬁnite). Therefore, we postulate mutations in
UBE1 to be the underlying disease causing genetic defects
for XL-SMA.
By a systematic analysis of human genetic variations, it
was determined recently that up to 70% of low-frequency
missense alleles are deleterious, suggesting that the low
allele frequency of a rare amino acid variant can, by itself,
serve as a predictor of its functional signiﬁcance.11 More-
over, the two missense mutations detected in families #5
and #7 are located in a part of the transcript that codes
for a highly conserved protein domain (Figure 3) that
forms interactions with gigaxonin.12 Allen and colleagues
describe gigaxonin as a member of the BTB/kelch super-
family that is important for axonal structure and neuronal
maintenance. By building complexes with UBE1, gigaxo-
nin controls the degradation of ubiquitin-mediated micro-
tubule-associated protein 1B (MAP1B). Because it interacts
with UBE1, gigaxonin was suggested to function as a scaf-
fold protein in the ubiquitin-proteasome system (UPS).
The authors showed that overexpression of gigaxonin
leads to enhanced degradation of MAP1B-LC, whereas
overexpression of MAP1B in wild-type cortical neurons
leads to cell death.12 Aberrations of the amino acid se-
quence in the interaction domain of UBE1, as caused by
Figure 2. Sequence Alterations Detected in Exon 15 of the
UBE1 Gene
(A) The synonymous c.1731 C/T substitution. Top, wild-type
sequence with the ‘‘C’’ highlighted in blue; center, heterozygote
status in an obligate carrier; bottom, C/T substitution in a patient
with the ‘‘T’’ highlighted in gray.
(B) The c.1617 G/T substitution, p.Met539Ile in family #5. Top,
wild-type sequence; center, heterozygote status of an obligate
carrier; bottom, G/T substitution in a patient.190 The American Journal of Human Genetics 82, 188–193, Januarythe two detected missense mutations, may well lead to a
disturbed complex building with gigaxonin and as a conse-
quence, to impairedMAP1B degradation. Thus, an increase
of MAP1B protein may enhance neuronal cell death with
negative consequences also in motorneurons.
In contrast to the two missense mutations, the synony-
mous C/T substitution detected in families #2, #4, and
#15 does not alter the protein sequence, so we ﬁrst per-
formed quantitative PCR experiments in lymphoblastoid
and ﬁbroblastoid cell lines of two index patients, respec-
tively (families #2 and #4) to investigate whether the alter-
ation may inﬂuence UBE1 expression in these cells. These
analyses revealed no expression differences in the two pa-
tients’ cell lines as compared to cell lines from healthy con-
trol individuals. The same result was obtained by western
blot analysis. Also, no differences in expression were de-
tectable in a cell line of the index patient of family #4 as
compared to healthy controls (data not shown). However,
as has been reported, UBE1 displays signiﬁcant differences
in gene expression depending on whether it is analyzed
in native tissue or in cell cultures derived from the same
biopsies.13 Therefore, we performed real-time PCR in white
blood cells of the still living index patient of family #15.
PCR ampliﬁcation and detection was performed on a
Sequence Detection System (ABI PRISM 7000, Applied Bio-
systems) applying the standard two-step protocol (45 cy-
cles, annealing temperature 61C) recommended by ABI.
The forward primer (CCC TGG GAT GTC ACG AAG TT)
was located at exon boundary 14–15, and the reverse
primer (ATG CGG GCA TCC ACG TT) at exon boundary
15–16. The speciﬁc probe (FAM-TCC GGG TGA CAA GCC
ACC AGA-TMR) was located in exon 15 (TIBMOLBIOL).
The genes for 18sRNA and HPRT were used as references
(ABI). These analyses revealed a reduction of expression
in the patient to one-ﬁfth as compared to blood cells of
three healthy controls, thereby implying an impact of the
synonymous substitution on gene expression. The conse-
quence of this substitution in the patients might be even
more prominent in developing spinal cord, in which UBE1
was shown to be highly expressed (P. Tsoulfas and P.M.
Wood, personal communication).
Although we could not detect any visible alternative
splice variants on agarose gels, we could not rule out that
the detected reduction of expression of the UBE1 wild-
type transcript was caused by aberrant splicing processes.
For this reason, we applied the in silico ESEﬁnder tool (re-
lease 2.0) to determine whether the synonymous C/T ex-
change may alter existing exonic splicing enhancer motifs
or introduce a novel one.14 This analysis revealed that the
exchange leads, in close proximity to another splice en-
hancer motif ‘‘GGACAACG,’’ to the generation of a second
putative exonic splice enhancer motif ‘‘TGTGGA.’’ This
new motif could be recognized by the SRp55 protein,
which belongs to a family of highly conserved splicing
factors that bind to ESEs and are able to promote exon def-
inition.14 It seems possible that the introduction of an
additional splice enhancer motif results in a competitive2008
Figure 3. Genomic Structure of the UBE1
Gene and Amino Acid Conservation of Exon
15 in Several Species
(A) Yellow boxes represent the 26 exons of UBE1
with an alternative exon 1a. The gene structure
was obtained from publicly available databases
(UCSC Genome Bioinformatics). Translation start
in exon 2 is indicated with a black arrow. Five ex-
onic CpG islands were detected by using in silico
CpG island prediction tools (MethPrimer).
(B) Position of CpG island and the methylated CpG
dinucleotides in exon 15 are represented by green
boxes. In index patients of three XL-SMA families,
one C methylation less is observed resulting from
the C/T exchange (red box). For bisulphite geno-
mic sequencing, genomic DNA was isolated from
cell lines or whole blood by means of the DNA
Extraction Mini Kit (QIAGEN). The bisulfite modifi-
cation reaction was performed with the EZ DNA
Methylation Kit (HISS Diagnostics), and the bisul-
fite-treated DNA was amplified with primer pair (1f, 50-GGT GAA TGT ATA AAT AAG TGA GT-30; 1r, 50-ACA CCC CTC TTA ATA TAT ACA C-30) and
subsequently sequenced with Big Dye kits (Perkin Elmer). The positions of the three detected mutations in exon 15 are marked with red stars.
(C) Exon 15 represents parts of the transcript that codes for a highly conserved protein domain that form interactions with gigaxonin. Amino
acid exchanges in the different species are highlighted in blue.inhibition of the two ESEs and thus alters the splicing pro-
cess in such a manner that the amount of wild-type tran-
script becomes reduced in favor of unstable, alternative
transcript variants.
We also considered and analyzed an alternative explana-
tion for the observed reduced UBE-1 expression seen in
association with the synonymous C/T substitution. As
shown in Figure 3, bisulﬁte genomic sequencing revealed
that the substitution involves one CpG dinucleotide out
of 13 CpGs that are methylated in healthy controls. These
13 CpGs form a 223 bp large CpG island that is mainly
located in exon 15 and partly in intron 15. Because of the
C/T exchange, the patients exhibit only 12 methylated
cytosins (Figure 3). DNA methylation is described to be
essential for normal mammalian embryonic development
because it alters the appearance of the major groove of the
DNA to which DNA binding proteins can bind.15,16 Meth-
ylation changes the interactions between these proteins
and the DNA, which leads to alterations in chromatin
structure and either to a decrease or an increase in the
rate of transcription. Whereas methylation of a promoter
CpG island leads to the binding of methylated CpG bind-
ing proteins and transcription repressors to block tran-
scription initiation, methylation of silencer and so-called
insulator elements impede the binding of cognate-binding
proteins that potentially abolishes their repressive activi-
ties on gene expression.16,17 In the case of UBE1, one may
speculate, that the detected methylated CpG island in
exon 15 harbors an element that acts in an insulator-like
manner. Although we found the promoter site of UBE1 to
be unmethylated (data not shown), themethylation of this
putative element might prevent the binding of speciﬁc
proteins that act as transcription repressors by blocking
speciﬁc transcription enhancer elements. In our favoredThe Ammodel (Figure 4), the observed C/Taberration would alter
the required methylation pattern at this site, and as a con-
sequence, the speciﬁc transcription repressors would bind
and possibly block speciﬁc transcription enhancers neces-
sary for required UBE1 expression.
Taken together, the presented data provide strong evi-
dence that the rare missense and synonymous mutations
detected in exon 15 of UBE1 are associated with X-linked
spinal muscular atrophy (XL-SMA). We strongly suggest
that an alteration of the UBE1-mediated ubiquitin-
proteasome system results in disturbed neuronal/motor-
neuron development, resulting in the XL-SMA disease
phenotype.
Ciechanover stated in his Nobel lecture in 2004 about
the ubiquitin-proteasome system that ‘‘with the multitude
of substrates targeted and processes involved, it is not sur-
prisingly that aberrations in the ubiquitin-proteasome
pathway have been implicated in the pathogenesis of
many diseases, among them certainmalignancies and neu-
rodegenerations.’’10 A growing list of neurodegenerative
disorders has been associated with primary or secondary
defects in ubiquination, primarily in the ubiquitin-pro-
teasome pathway.18 For example, mutations in Parkin
(PARK2), an E3 ligase (MIM *602544), or the ubiquitin car-
boxy-terminal hydrolase L1 (UCHL1 [MIMþ191342]) have
been demonstrated in patients with Parkinson’s disease
(PDJ, PD [MIM #600116, MIM #168600]).18 Very recently,
mutations in the CUL4B gene (MIM *300304), encoding
an E3 ligase subunit, were found to be causative for an
X-linked form ofmental retardation associated with neuro-
logical features like tremor, seizures, ataxia, and wasting
of calf muscles (MIM #300354).19 To date, pathogenic mu-
tations in human UBE1 have not been reported and we
report here the ﬁrst ones for this gene, associated with anerican Journal of Human Genetics 82, 188–193, January 2008 191
Figure 4. Model for Suggested Tran-
scription Regulatory Element in Exon
15 of UBE1
(A) In the wild-type, the CpG island in exon
15 is fully methylated (symbolized by four
green cylinders), which prevents the bind-
ing of proteins (red diamond) that block
a specific transcription enhancer element,
thus allowing a putative enhancer to stim-
ulate the transcription.
(B) In the XL-SMA patient harboring the
synonymous C/T exchange, the CpG is-
land in exon 15 is only partly methylated
(symbolized by a white cylinder among
three green cylinders), thus allowing the
proteins to bind and as a consequence
the transcription enhancer is blocked.early-onset neurodegenerative disorder involving lower
motor neurons. Moreover, the knowledge that SMN, the
protein affected in AR-SMA, is also degraded via the ubiq-
uitin-proteasome pathway may well provide important
clues into our understanding of common disease mecha-
nisms that produce anterior horn cell death in early child-
hood, as well as provide hope for design of therapeutic
interventions for these biologically related, but genetically
distinct, fatal childhood disorders.20
Acknowledgments
The authors are grateful to the numerous clinicians and families
that have supported these studies through their cooperation
throughout the years. In particular, we would like to acknowledge
the contributions of Dr. R. Best and J. Edwards (University of South
Carolina Medical Center); R.D.C. and her genetic counselling staff
(Loma LindaMedical Center); Drs. D. Rita, C. Booth, and E. Moran
(Lutheran General Hospital); Dr. R. Martin (St. Louis University);
Dr. K. Flannigan (University of Utah School of Medicine); and
Dr. S. Sacharow (Dr. John T. Macdonald Center for Medical Genet-
ics, Miami). We would also like to thank Baylor College of Medi-
cine, Institute of Human Genetics Cell Line facility (J. Belmont,
M.D., Director), and the University of Miami Gene Cure Cytoge-
netics Laboratory (Y.-S. Fan, M.D., Director) for the establishment
and maintenance of family cell lines. We would like to thank the
German Breast Cancer Consortium for providing DNA samples.
We would also like to acknowledge the helpful discussions and in-
formation provided by Dr. S. Khuri (Dr. John T. Macdonald Center
for Medical Genetics, Miami, FL) and the guidance of Drs. R. Ho-
well, W. Bradley, and L. Elsas throughout the course of these stud-
ies. We also thank Dr. B. Mueller-Myhsok for support in statistical
analysis and M. Bertone for technical assistance. This work was
supported in the United States by funds from the Dr. John T. Mac-
donald Center for Medical Genetics, University of Miami—Miller
School of Medicine and the University of Miami—Miller School
of Medicine (to L.B.-R.). The national Muscular Dystrophy Associ-
ation and the Families of SMA have also provided past support to
L.B.-R. and E.P.H. for these investigations. This work was sup-192 The American Journal of Human Genetics 82, 188–193, Januaryported in Europe by the GermanMinistry for Research and Educa-
tion grant BMBF 01KW9974 (to A.M.). C.L. was supported by the
FAZIT-Stiftung, Frankfurt/Main, Germany.
Received: July 25, 2007
Revised: August 29, 2007
Accepted: September 6, 2007
Published online: January 10, 2008
Web Resources




NCBI SNP database, http://www.ncbi.nlm.nih.gov/SNP/
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